BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26242353)

  • 1. Authors' Reply to "Pituitary Atypical Adenoma or Carcinoma Sensitive to Temozolomide Combined with Radiation Therapy: A Case Report of Early Identification and Management".
    Curtò L; Trimarchi F
    Turk Neurosurg; 2015; 25(4):679-80. PubMed ID: 26242353
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on "Non-surgical treatment of hormone-secreting pituitary tumors".
    Dobson M; Del Porto L; Maartens NF
    J Clin Neurosci; 2010 Sep; 17(9):1220-1. PubMed ID: 20570519
    [No Abstract]   [Full Text] [Related]  

  • 3. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
    Curtò L; Torre ML; Ferraù F; Pitini V; Altavilla G; Granata F; Longo M; Hofland LJ; Trimarchi F; Cannavò S
    ScientificWorldJournal; 2010 Nov; 10():2132-8. PubMed ID: 21057727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
    Zhong C; Yin S; Zhou P; Jiang S
    Turk Neurosurg; 2014; 24(6):963-6. PubMed ID: 25448217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-lasting complete remission after therapy with temozolomide in two patients with macrocorticotropinoma causing Cushing's disease.
    Bruno OD; Juárez-Allen L; Christiansen SB; Danilowicz K
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):143-5. PubMed ID: 25611185
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of pituitary neoplasms with temozolomide: A review.
    Marucci G
    Cancer; 2011 Sep; 117(17):4101-2; author reply 4102. PubMed ID: 21387270
    [No Abstract]   [Full Text] [Related]  

  • 7. Atypical, invasive, recurring Crooke cell adenoma of the pituitary.
    Rotondo F; Cusimano M; Scheithauer BW; Coire C; Horvath E; Kovacs K
    Hormones (Athens); 2012; 11(1):94-100. PubMed ID: 22450349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide and pituitary adenoma.
    Hueng DY; Ma HI; Sytwu HK; Liu MY
    J Neurosurg; 2011 Jun; 114(6):1820: author reply 1820-1. PubMed ID: 21513431
    [No Abstract]   [Full Text] [Related]  

  • 9. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
    Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a role for early chemotherapy in the management of pituitary adenomas?
    Lin AL; Sum MW; DeAngelis LM
    Neuro Oncol; 2016 Oct; 18(10):1350-6. PubMed ID: 27106409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
    Strowd RE; Salvatori R; Laterra JJ
    J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
    Zacharia BE; Gulati AP; Bruce JN; Carminucci AS; Wardlaw SL; Siegelin M; Remotti H; Lignelli A; Fine RL
    Neurosurgery; 2014 Apr; 74(4):E447-55; discussion E455. PubMed ID: 24226425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of temozolomide in the treatment of aggressive pituitary tumors.
    Liu JK; Patel J; Eloy JA
    J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pituitary disease: which treatment in the future?].
    Briet C; Chanson P
    Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S2-7. PubMed ID: 22008273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimodality treatment of pituitary adenomas.
    Oyesiku NM
    Clin Neurosurg; 2005; 52():234-42. PubMed ID: 16626076
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-VEGF therapy in pituitary carcinoma.
    Ortiz LD; Syro LV; Scheithauer BW; Ersen A; Uribe H; Fadul CE; Rotondo F; Horvath E; Kovacs K
    Pituitary; 2012 Sep; 15(3):445-9. PubMed ID: 21918831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical approach to pituitary tumors.
    Neggers SJ; van der Lely AJ
    Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of temozolomide in aggressive pituitary tumors: case report.
    Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
    Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
    Gilis-Januszewska A; Wilusz M; Pantofliński J; Turek-Jabrocka R; Sokołowski G; Sowa-Staszczak A; Kluczyński Ł; Pach D; Zieliński G; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2018; 69(3):306-312. PubMed ID: 29319131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.